One-year results for STELARA in Crohn’s disease - The head-to-head SEAVUE Study

Returning guest, Dr. Andrew Greenspan, Vice President of Immunology Medical Affairs at Janssen discusses recent data from the Phase 3b SEAVUE study, the first head-to-head study of biologic therapies in patients with Crohn’s disease, evaluating the safety and efficacy of STELARA® (ustekinumab) compared with adalimumab through one year of treatment in biologic-naïve patients. These data were presented at this year’s Digestive Disease Week (DDW) Virtual 2021, where Janssen Immunology presented 20 abstracts in total from the company’s gastroenterology portfolio and pipeline.

#Immunology #CrohnsDisease #IBD

Видео One-year results for STELARA in Crohn’s disease - The head-to-head SEAVUE Study канала HPR